Paul Weiss Rifkind Wharton & Garrison

Paul Weiss Rifkind Wharton & Garrison is highly ranked for its strength in general patent litigation, notably in biosimilars disputes and post-grant proceedings. "Their trial attorneys have a deep understanding of the technology at issue and are quick on their feet," a peer says. Paul Weiss has one of the pioneering practices in biosimilars litigation, a continuing area of focus for the firm.

The firm's position as a leading practice in the large molecule space is in part due to litigator Nicholas Groombridge, an IP trial lawyer with more than 25 years of experience. One peer says Groombridge is "doing a bang-up job in biologics," while another offers, "He's a good lawyer, not only on his feet, but also a good writer as well." He also has deep experience in patent disputes related to pharmaceuticals and medical devices. Groombridge was shortlisted as the New York General Patent Litigator of the Year in 2019 for his involvement in the noteworthy patent case Vanda v West-Ward Pharmaceuticals.

DC-based partner Steven Baughman is a leading practitioner for post-grant proceedings. His past representations include IPRs for Nevro Corporation and Chugai Pharmaceutical.

Eric Stone is another standout in the firm's roster of stars for his significant work in patent litigations involving large and small molecule products. "I think Eric is quite extraordinary," a peer says, adding he is "one of the best advocates I have seen in court." Another peer says: "Eric is one of the finest attorneys that I have come across. His knowledge of biotechnology allows him to run circles around the competition."